Prediction of 2-year carcinogenicity study results for pharmaceutical products: How are we doing?

Toxicological Sciences

Volumn 88, Issue 1, 2005, Pages 18-23

  Jacobs, Abigail ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Carcinogenicity; Drug; Genetic toxicology

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR AFFECTING AGENT; MINERALOCORTICOID ANTAGONIST; MONOAMINE OXIDASE INHIBITOR; NUCLEOSIDE ANALOG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROLACTIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; TACHYKININ RECEPTOR ANTAGONIST; XANTHINE OXIDASE INHIBITOR;

ACCURACY; ADRENAL CANCER; AREA UNDER THE CURVE; BLADDER CANCER; BLADDER CARCINOGENESIS; BREAST CANCER; BREAST CARCINOGENESIS; CARCINOGEN TESTING; CELL PROLIFERATION; CHEMICAL MUTAGENESIS; CORRELATION ANALYSIS; CYTOTOXICITY; DATA ANALYSIS; DATA BASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CARCINOGENICITY; GASTROINTESTINAL TOXICITY; GENETIC TOXICOLOGY; HUMAN; KIDNEY CANCER; LEUKEMIA; LIVER HYPERTROPHY; LIVER TOXICITY; LUNG CANCER; LYMPHOMA; MAXIMUM TOLERATED DOSE; MUTAGEN TESTING; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OUTCOMES RESEARCH; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RELIABILITY; REVIEW; THYROID FOLLICULAR CARCINOMA;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; DRUG EVALUATION, PRECLINICAL; FEMALE; INTERNATIONAL COOPERATION; MALE; MICE; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; RATS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 27644441505     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfi248     Document Type: Review

References (10)

1. Allen, D. G., Pearse, G., Haseman, J. K., and Maronpot, R. R. (2004). Prediction of rodent carcinogenesis: An evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol. Pathol. 32, 393-401.
2. Cohen, S. M. (2004). Human carcinogenic risk evaluation: An alternative approach to the two-year rodent bioassay. Toxicol. Sci. 80, 225-229.
3. ICH S1B, International Conference on Harmonization ICH S1B. (1997). Guidance for Industry S1B Testing for Carcinogenicity of Pharmaceuticals. http://www.fda.gov/cder/guidance/index.htm.
4. ICH S2B, International Conference on Harmonization ICH S2b. (1997). Guidance for Industry Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals. www.fda.gov/cder/guidance/index.htm.
5. ICH S1C, International Conference on Harmonization ICH S1C. (1995). Dose Selection for Carcinogenicity Studies of Pharmaceuticals. www.fda.gov/cder/guidance/index.htm.
6. ICH S1C(R), International Conference on Harmonization ICH S1C(R). (1997). Guidance on Dose Selection for Carcinogenicity Studies of Pharmaceuticals: Addendum on a Limit Dose and Related Notes. www.fda.gov/cder/guidance/index.htm.
7. MacDonald, J. S. (2004). Human carcinogenic risk evaluation, Part IV: Assessment of human risk of cancer from chemical exposure using a global weight-of-evidence approach. Toxicol. Sci. 82, 3-8.
8. MacDonald, J., French, J. E., Gerson, R. J., Goodman, J., Inoue, T., Jacobs, A., Kasper, P., Keller, D., Lavin, A., Long, G., et al. (2004). The utility of genetically modified mouse assays for identifying human carcinogens: A basic understanding and path forward. Toxicol. Sci. 77, 188-194.
9. Melnick, R. L., Kohn, M. C., Portier, and C. J. (1996). Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis. Environ. Health Perspect. 104 (Suppl. 1), 123-134.
10. Zeiger, E. (1998). Identification of rodent carcinogens and noncarcinogens using genetic toxicity tests: Premises, promises, and performance. Regul. Toxicol. Pharmacol. 28, 85-95.